"OH say you OTC, buy the dawn's daily plight" ; - )My suggestion would be to deal in the "fact trade" ....here are a few for fellow retail holders.......
* The OTC PINKs here in the US are not really the place to gain recognition or respect. With a market cap of less than 75M USD, detail reveals mostly short trading and a listing that few serious US investers would ever truly consider - IMHO. Moving "voluntarily" to this exchange has allowed for in excess of 50M shares to be printed without ANY newsflow to the only NA market that really cares about what the company is doing - the US. Canada has had approval of both the EAA ( FDA approved in 2003 ) and PMX for nearly 20 years and done nothing with it. This is a US / FDA story, trading SHORT on the lowest rung of the US OTC PINKs should be analyzed closely, as should it's timing, maintenance and of course decision to hire US IR. What can they really do with the "organized cards they've been dealt"?
That said, the AGP Investment company based out of New York did take 23 MILLION shares of EDTXF in a "bought deal" ( July 2021 ) at 42.5 cents CAD and that included about 11.5 MILLION warants exercisable at 50 cents CAD. They have a biotech / health care analyst I have heard wonderful things about. His name is James Malloy, I am hopeful he is aware of the purchase and even more hopeful he chooses to write a report or "initiate coverage" on Spectral. In my humble opinion, our healthy stable of scientific advancemant for a company valued at about 60 MILLION USD is well worthy of a "real analyst". Bear in mind though, few ( if any ) real analysts pick up serious coverage on stocks trading well below a 100M USD market cap, and mostly "SHORT" ( according to the US OTC short report ) on the lowest / NON-reporting level of the US OTC PINKs. If a low ACB and little attention is desired, then this is your exchange. I have a hard time imagining why there was any other reason to "voluntarily DELIST to this level.
Spectral Medical Inc.December 14, 2016 08:00 ET
Spectral Voluntarily Delists From OTCQX
TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) -Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product Toraymyxin™ ("PMX") for the treatment of patients with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Currently there is no specific treatment available for this condition.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com
Love the company though....I just happen to have more "patience" than most...I guess ; - )
Wishing you ALL well, and paying close attention to activity in our "public sandbox" ; - )
Bon appetito,
Thomas A Tractor